Biocept and OvaScience Post Gains Amid Investor Speculation

NEW YORK, NY / ACCESSWIRE / March 23, 2017 / The news for both Biocept and OvaScience is that investors will have to await further news to see if today’s gains hold. Biocept investors are awaiting news on the presentation the company made at a conference today, while OvaScience investors look for clues to the reasons for today’s bump. An increased trading volume caused investors to take a second look at the stocks for their upside potential.

RDI Initiates
Coverage:

Biocept Inc. https://ub.rdinvesting.com/news/?ticker=BIOC

OvaScience Inc. https://ub.rdinvesting.com/news/?ticker=OVAS

Stock analysts were impressed by Biocept’s stock movement on Wednesday, the company’s stock was up $0.16 to close at $2.34. One noticeable thing was the trading volume that reached more than 2.8 million shares on the day, the stock has trended upward since early November of last year. The company is involved in the development of early cancer diagnostic technologies. It made a presentation on Wednesday, March 22nd at the 27th Annual Oppenheimer Healthcare Conference, and as a result investors are showing their optimism and are awaiting a report from the company on the results of the conference presentation. After hours trading has the company’s stock down slightly.

Access RDI’s Biocept Research Report at: https://ub.rdinvesting.com/news/?ticker=BIOC

Some investors took a long position on OvaScience on Wednesday as the company is sparking long term interest on the continued development of one of its fertility treatment options for women, available worldwide. OvaPrime is intended to avoid hormone treatment therapy injections by producing mature fertilizable eggs from the woman’s own EggPC cells, it is currently enrolling for company sponsored trials that will complete in the first half of 2017. With $114.4 million in cash, cash equivalents and short term investments as on December 31, 2016, the company finds itself sufficiently funded to progress the clinical development of OvaPrime, at least until the end of 2018. The stock closed at $1.72 a share, up $0.12 on the day. While the consensus of analysts called for a “hold” on the stock, it appears the stock will approach $2 per share. On Wednesday, the stock traded fairly evenly, but both the 5 day and the 30 day trends show a consistent rise in price. After hours trading continued the rise, edging up another $0.02.

Access RDI’s OvaScience Research Report at: https://ub.rdinvesting.com/news/?ticker=OVAS

Our Actionable Research on Biocept Inc. (NASDAQ: BIOC) and OvaScience Inc. (NASDAQ: OVAS) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458006